Here are four things to know:
1. There is a growing trend for hospital department-wide strategies to prevent HAIs.
2. The diagnosis segment of the market is growing fast, due to increased infection awareness.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox
3. However, the treatment segment of the HAI control market has struggled to maintain growth. This is primarily due to a weak development pipeline and growing drug resistance.
4. Kenilworth, N.J.-based Merck & Co., New York City-based Pfizer, Brentford, United Kingdom-based GlaxoSmithKline and Leverkusen, Germany-based Bayer are key players in the market.
More articles on quality:
8 hospitals in Maryland with top nurse-patient communication scores
Wyoming hospital urged to contact patients after unsterile surgical instrument reports
On the brink: 3 dangers of inadequate surgical instrument reprocessing departments
